TAK-536, a New AT1 Receptor Blocker, Improves Glucose Intolerance and Adipocyte Differentiation

American Journal of Hypertension

Volumn 20, Issue 5, 2007, Pages 579-586

  Iwai, Masaru ^a   Chen, Rui ^a   Imura, Yoshimi ^b   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

adipocyte differentiation; adiponectin; AT1 receptor blocker; Diabetes; insulin resistance; tumor necrosis factor

Indexed keywords

2 ETHOXY 1 [[2' (5 OXO 2,5 DIHYDRO 1,2,4 OXADIAZOL 3 YL)BIPHENYL 4 YL]METHYL] 1H BENZIMIDAZOLE 7 CARBOXYLIC ACID; ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ADIPOCYTES; ADIPOSE TISSUE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; CELL DIFFERENTIATION; CELL SIZE; EATING; GLUCOSE; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; MALE; MICE; MUSCLE, SKELETAL; OXADIAZOLES; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247581728     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.12.010     Document Type: Article

References (20)

1. Shinozaki K., Ayajiki K., Nishio Y., Sugaya T., Kashiwagi A., and Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43 (2004) 255-262
2. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujimoto M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., and Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 (2002) 872-879
3. DeFrondo R.A., and Ferrannini E. Insulin resistance: a multifaced syndrome responsible for cardiovascular diseases. Diabetes Care 14 (1991) 173-194
4. DeFrondo R.A. Insulin resistance, hyperinsulinemia and coronary artery diseases. J Cardiovasc Pharmacol 20 Suppl (1992) S1-S16
5. Abuissa H., Jones P.G., Marso S.P., and O'Keefe J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
6. Furuhashi M., Ura N., Takizawa H., Yoshida D., Moniwa N., Murakami H., Higashiura K., and Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22 (2004) 1977-1982
7. Ura N., Higashiura K., and Shimamoto K. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immuno pharmacology 44 (1999) 153-159
8. Togashi N., Ura N., Higashiura K., Murakami H., and Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18 (2000) 1605-1610
9. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., Okumura M., Cui T.X., and Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 (2004) 1003-1010
10. Kohara Y., Kubo K., Imamiya E., Wada T., Inada Y., and Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazol bioisosters. J Med Chem 39 (1996) 5228-5235
11. Fenton C., and Scott L.J. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs 65 (2005) 537-558
12. Weber M., Glasser S., Scheffler M., Lessem J., Obayahi M., Dennick L., Harrisson M., and Drayer J. A dose finding study with a potent angiotensin II receptor antagonist-TAK-536. J Hypertens 14 Suppl (1996) s230 (Abstract)
13. Shiuchi T., Cui T.X., Wu L., Nakagami H., Takeda-Matsubara Y., Iwai M., and Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40 (2002) 329-334
14. Sudo M., Minokoshi Y., and Shimazu T. Ventromedial hypothalamus stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol 261 (1991) E298-E303
15. Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J.R., and Pedersen B.K. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of AKD substrate 160 phosphorylation. Diabetes 54 (2005) 2939-2945
16. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
17. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
18. Wang B., Jenkins J.R., and Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-α. Am J Physiol Endocrinol Metab 288 (2005) E731-E740
19. Yvan-Charvet L., Even P., Bloch-Faure M., Guerre-Millo M., Moustaid-Moussa N., Ferre P., and Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54 (2005) 991-999
20. Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 25 (2005) 485-512